[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Wang et al., 2022 - Google Patents

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

Wang et al., 2022

View HTML @Full View
Document ID
14958975407483326902
Author
Wang D
Wu X
Sun Y
Publication year
Publication venue
Signal transduction and targeted therapy

External Links

Snippet

Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression. Immunotherapy …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Wang et al. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Gaynor et al. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
US11944647B2 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
Khair et al. Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma
Osipov et al. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Khalil et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Wang et al. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Pianko et al. Immune checkpoint blockade for hematologic malignancies: a review
Mahoney et al. Combination cancer immunotherapy and new immunomodulatory targets
Melaiu et al. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Ribas Clinical development of the anti–CTLA-4 antibody tremelimumab
AU2013289967B2 (en) Toxicity management for anti-tumor activity of CARs
US20190358262A1 (en) Methods for modulation of car-t cells
CN111727373A (en) Chimeric antigen receptor targeting BCMA and uses thereof
Honeychurch et al. Immuno-regulatory antibodies for the treatment of cancer
CN110691795A (en) Compositions comprising anti-LAG 3 antibodies, PD-1 pathway inhibitors, and immunotherapeutic agent combinations
Jackson et al. Targeting CD8+ T-cell tolerance for cancer immunotherapy
Borrie et al. T Lymphocyte–Based Cancer Immunotherapeutics
Wang et al. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers
Haddad et al. Resistance to immune checkpoint blockade: Mechanisms, counter-acting approaches, and future directions
Yu et al. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy
Mejía-Guarnizo et al. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy
Liu et al. Immune checkpoint inhibitors for multiple myeloma immunotherapy
Peng et al. A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy
US20220008465A1 (en) Methods of dosing engineered t cells for the treatment of b cell malignancies